| Title | Mutability and hypermutation antagonize immunoglobulin codon optimality. |
| Publication Type | Journal Article |
| Year of Publication | 2025 |
| Authors | McGrath JJC, Park J, Troxell CA, Chervin JC, Li L, Kent JR, Changrob S, Fu Y, Huang M, Zheng N-Y, G Wilbanks D, Nelson SA, Sun J, Inghirami G, Madariaga MLucia L, Georgiou G, Wilson PC |
| Journal | Mol Cell |
| Volume | 85 |
| Issue | 2 |
| Pagination | 430-444.e6 |
| Date Published | 2025 Jan 16 |
| ISSN | 1097-4164 |
| Keywords | Animals, Antibodies, Monoclonal, Codon, Complementarity Determining Regions, COVID-19, HIV-1, Humans, Immunoglobulin G, Immunoglobulin Heavy Chains, Immunoglobulin Variable Region, Mice, Mutation, SARS-CoV-2, Somatic Hypermutation, Immunoglobulin, V(D)J Recombination, Zebrafish |
| Abstract | The efficacy of antibody responses is inherently linked to paratope diversity, as generated through V(D)J recombination and somatic hypermutation. Despite this, it is unclear how genetic diversification mechanisms evolved alongside codon optimality and affect antibody expression. Here, we analyze germline immunoglobulin (IG) genes, natural V(D)J repertoires, serum IgG, and monoclonal antibody (mAb) expression through the lens of codon optimality. Germline variable genes (IGVs) exhibit diverse optimality that is inversely related to mutability. Hypermutation deoptimizes heavy-chain (IGH) VDJ repertoires within human tonsils, bone marrow, lymph nodes (including SARS-CoV-2-specific clones), blood (HIV-1-specific clones), mice, and zebrafish. Analyses of mutation-affected codons show that targeting to complementarity-determining regions constrains deoptimization. Germline IGHV optimality correlates with serum variable fragment (VH) usage after influenza vaccination, while synonymous deoptimization attenuated mAb yield. These findings provide unanticipated insights into an antagonistic relationship between diversification mechanisms and codon optimality. Ultimately, the need for diversity takes precedence over that for the most optimal codon usage. |
| DOI | 10.1016/j.molcel.2024.11.033 |
| Custom 1 | |
| Alternate Journal | Mol Cell |
| PubMed ID | 39708804 |
| PubMed Central ID | PMC12063209 |
| Grant List | U19 AI168632 / AI / NIAID NIH HHS / United States U01 AI153700 / AI / NIAID NIH HHS / United States 75N93019C00051 / AI / NIAID NIH HHS / United States U01 AI165452 / AI / NIAID NIH HHS / United States INV-004956 / GATES / Gates Foundation / United States U01 AI144616 / AI / NIAID NIH HHS / United States P01 AI165077 / AI / NIAID NIH HHS / United States 75N93021C00014 / AI / NIAID NIH HHS / United States |
